Lorecivivint Emerging Drug Insight and Market Forecast - 2032

“Lorecivivint Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about lorecivivint for knee osteoarthritis (OA) in the seven major markets. A detailed picture of the lorecivivint for knee osteoarthritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the lorecivivint for knee osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the lorecivivint market forecast analysis for knee osteoarthritis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in knee osteoarthritis.

Drug Summary

Lorecivivint (SM04690) is a small-molecule inhibitor of the Wnt pathway administered as an intra-articular injection and is in development as a potential disease-modifying drug for osteoarthritis (OA) (DMOAD). Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three effects on joint health: the generation of cartilage, slowing of cartilage breakdown, and reduction of inflammation. Inhibition of nuclear kinases CLK2 and DYRK1A affects the Wnt pathway, chondrocytes, and inflammation. This dual mechanism of LOR potentially modifies OA through increased chondrocyte differentiation and function and benefits symptoms through anti-inflammatory activity.

Currently, lorecivivint (SM04690) is in the Phase III clinical development stage and is undergoing a Phase III clinical trials (NCT04520607) and has completed two Phase III trials (NCT03928184 [STRIDES-X-ray] and NCT04385303 [STRIDES-1].

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the lorecivivint description, mechanism of action, dosage and administration, research and development activities in knee osteoarthritis.
• Elaborated details on lorecivivint regulatory milestones and other development activities have been provided in this report.
• The report also highlights the lorecivivint research and development activities in knee osteoarthritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around lorecivivint.
• The report contains forecasted sales of lorecivivint for knee osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for knee osteoarthritis.
• The report also features the SWOT analysis with analyst views for lorecivivint in knee osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lorecivivint Analytical Perspective

In-depth Lorecivivint Market Assessment

This report provides a detailed market assessment of lorecivivint for knee osteoarthritis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Lorecivivint Clinical Assessment

The report provides the clinical trials information of lorecivivint for knee osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for knee osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence lorecivivint dominance.
• Other emerging products for knee osteoarthritis are expected to give tough market competition to lorecivivint and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of lorecivivint in knee osteoarthritis.
• Our in-depth analysis of the forecasted sales data of lorecivivint from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the lorecivivint in knee osteoarthritis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of lorecivivint?
• What is the clinical trial status of the study related to lorecivivint in knee osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the lorecivivint development?
• What are the key designations that have been granted to lorecivivint for knee osteoarthritis?
• What is the forecasted market scenario of lorecivivint for knee osteoarthritis?
• What are the forecasted sales of lorecivivint in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to lorecivivint for knee osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of knee osteoarthritis?